Published in Mayo Clin Proc on February 27, 2013
Clinical Management of Acute Portal/Mesenteric Vein Thrombosis. Viszeralmedizin (2014) 0.91
Small bowel stricture as a late sequela of superior mesenteric vein thrombosis. Int J Surg Case Rep (2014) 0.79
Initial transcatheter thrombolysis for acute superior mesenteric venous thrombosis. World J Gastroenterol (2014) 0.78
Mesenteric venous thrombosis. J Clin Exp Hepatol (2014) 0.76
Portomesenteric venous thrombosis following major colon and rectal surgery: incidence and risk factors. Surg Endosc (2014) 0.76
Additional information on mesenteric venous thrombosis. Mayo Clin Proc (2013) 0.76
Acute mesenteric venous thrombosis with a vaginal contraceptive ring. West J Emerg Med (2014) 0.75
Schistosomiasis Presenting as a Case of Acute Appendicitis with Chronic Mesenteric Thrombosis. Can J Infect Dis Med Microbiol (2016) 0.75
Mesenteric vein thrombosis caused by secondary polycythaemia from AndroGel. BMJ Case Rep (2014) 0.75
Mesenteric vein thrombosis in a patient heterozygous for factor V Leiden and G20210A prothrombin genotypes. World J Gastroenterol (2013) 0.75
Image Diagnosis: Inferior Mesenteric Vein Thrombosis. Perm J (2015) 0.75
Transcatheter thrombolysis combined with damage control surgery for treatment of acute mesenteric venous thrombosis associated with bowel necrosis: a retrospective study. World J Emerg Surg (2015) 0.75
Combination Therapy of Interventional Radiology and Surgery for Infarction of the Small Intestine Caused by Portal Vein and Mesenteric Vein Thrombosis: A Patient Report. Yonago Acta Med (2016) 0.75
Hepatobiliary quiz-12 (2014). J Clin Exp Hepatol (2014) 0.75
D-dimer as an early marker of severity in patients with acute superior mesenteric venous thrombosis. Medicine (Baltimore) (2014) 0.75
Diverticular Pylephlebitis and Polymicrobial Septicemia. Case Rep Infect Dis (2017) 0.75
Superior mesenteric vein thrombosis as an early presentation of myelodysplastic syndrome: a case report. Intest Res (2014) 0.75
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm. Medicine (Baltimore) (2016) 0.75
Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis. Exp Ther Med (2017) 0.75
Giant cavernous hemangioma coexistent with diffuse hepatic hemangiomatosis presenting as portal vein thrombosis and hepatic lobar atrophy. Ultrasonography (2013) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med (2013) 5.19
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (2010) 5.00
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol (2010) 4.18
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
The Budd-Chiari syndrome. N Engl J Med (2004) 3.95
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer (2007) 3.89
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Splanchnic artery aneurysms. Mayo Clin Proc (2007) 2.55
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood (2009) 2.51
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood (2004) 2.40
Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc (2006) 2.38
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood (2002) 2.34
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology (2014) 2.27
Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology (2008) 2.26
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood (2007) 2.25
Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology (2006) 2.25
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res (2009) 2.19
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood (2007) 2.04
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood (2004) 1.97
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med (2011) 1.96
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Performance standards for therapeutic abdominal paracentesis. Hepatology (2004) 1.93
Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol (2010) 1.90
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant (2004) 1.87
Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin (2009) 1.87
Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl (2007) 1.86
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl (2003) 1.83
Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc (2003) 1.82
Hepatocellular carcinoma after the Fontan procedure. N Engl J Med (2013) 1.81
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol (2005) 1.81
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood (2012) 1.77
Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. Crit Care Med (2003) 1.76
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood (2011) 1.73
Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest (2005) 1.72
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell (2008) 1.71
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol (2009) 1.69
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology (2003) 1.65
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood (2002) 1.64
Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc (2007) 1.64
Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol (2010) 1.62
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol (2014) 1.58
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology (2004) 1.57
Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol (2011) 1.54
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma (2008) 1.53
Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc (2004) 1.52
Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res (2003) 1.50
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc (2002) 1.47
Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet (2003) 1.47
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood (2012) 1.46
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer (2007) 1.46
Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol (2010) 1.46
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood (2004) 1.45
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol (2012) 1.44
LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med (2010) 1.43
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol (2014) 1.42
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer (2006) 1.42
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood (2010) 1.41
The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res (2003) 1.40
Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (2002) 1.40
Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica (2004) 1.40
Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation. Liver Transpl (2007) 1.39
Medical and surgical treatment options for polycystic liver disease. Hepatology (2010) 1.39
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
Myeloproliferative Neoplasms. N Engl J Med (2017) 1.38
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood (2009) 1.38
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood (2002) 1.38